Sonntag, 28. April 2024
Navigation öffnen
Anzeige:
Wefra Programatic
 
JOURNAL ONKOLOGIE – STUDIE

Role of Intrapulmonary Lymph Nodes in Patients With NSCLC and Visceral Pleural Invasion

Rekrutierend

NCT-Nummer:
NCT05596578

Studienbeginn:
Januar 2023

Letztes Update:
09.01.2023

Wirkstoff:
-

Indikation (Clinical Trials):
Lymphatic Metastasis

Geschlecht:
Alle

Altersgruppe:
Erwachsene (18+)

Phase:
-

Sponsor:
Luzerner Kantonsspital

Collaborator:
-

Kontakt

Studienlocations
(1 von 1)

Studien-Informationen

Brief Summary:

Background: Lung cancer is the leading cause of cancer related death worldwide. More than 80%

of all lung tumors are Non-Small Cell Lung Cancers (NSCLC). Lymph node staging has a

prognostic value and is crucial to establish the optimal treatment strategy in individual

patients. It remains unknown whether dissecting the intrapulmonary lymph nodes (stations 13

and 14) is necessary for accurate staging and prognostication. Although suggested by several

guidelines, these peripheral lymph nodes are not routinely examined in clinical routine for

several reasons. Moreover, the prognostic significance of the visceral pleural invasion is

controversial. Some studies showed a negative impact on OS and DFS in patients with

histologic proved visceral pleura invasion.

The mechanism to explain this negative effect is not fully understood. Given that the

visceral pleura is very rich in lymphatic vessels, with an intercommunicating "network"

arranged over the lung surface and penetrating into the lung parenchyma to join the bronchial

lymph vessels with drainage to the various hilar nodes, we assume that the worse OS and DFS

observed in these patients could be explained with the presence of metastatic lymph nodes

(Station 13-14) that are not routinely examined. Methods: This is a prospective, multicenter

study based on ad-hoc created prospectively database. The incidence of N1 lymph node

metastasis overall and the incidence of metastasis to the different lymph node stations

(Hilar 10/11, Lobar 12, Sublobar 13/14) will be calculated by dividing the number of the

respective events by the patient years separately. To investigate the association between

visceral pleural invasion and the presence of metastatic lymph nodes univariate and

multivariate logistic regression models will be fitted to the data.

Discussion: The primary outcome is to investigate the incidence of N1 metastases (especially

stations 12,13,14) and his relationship with visceral pleural invasion. The secondary

outcomes is to evaluate the impact of N1 metastases and/or visceral pleural invasion on

long-term outcomes (OS and DFS) along with incidence and pattern of recurrence. DFS is

defined as the time of surgical intervention to tumor recurrence or death, and OS is defined

as the time of surgical intervention to death

Ein-/Ausschlusskriterien

Inclusion Criteria:

- Anatomical resection for NSCLC <3 cm (lobectomy, bilobectomy, segmentectomy)

- Samples from the intrapulmonary stations 12, 13, and 14 lymph nodes

- Resection of lymphnodes station 10 and 11 during hilar separation.

- R0 resection

Exclusion Criteria:

- Prior or synchronous lung cancer

- pN2

- Pneumonectomy

- R1/R2 resection

- M1

- Neoadjuvant treatment

Studien-Rationale

Primary outcome:

1. N1 (Time Frame - January 2023-December 2024):
Overall incidence of N1 pathological lymph nodes (Hilar 10/11, Lobar 12, Sublobar 13/14)

2. VPI (Time Frame - January 2023-December 2024):
Incidence of N1 pathological lymph nodes (Hilar 10/11, Lobar 12, Sublobar 13/14) in patients with pathological evidence of visceral pleural invasion

Secondary outcome:

1. OS (Time Frame - January 2023- December 2029):
Overall Survival (1-3-5 Years)

2. DFS (Time Frame - January 2023-December 2029):
Disease free survival (1-3-5 Years)

3. Tumor recurrence (Time Frame - January 2023-December 2029):
pattern : local, regional, distant

Quelle: ClinicalTrials.gov


Sie können folgenden Inhalt einem Kollegen empfehlen:

"Role of Intrapulmonary Lymph Nodes in Patients With NSCLC and Visceral Pleural Invasion"

Bitte tragen Sie auch die Absenderdaten vollständig ein, damit Sie der Empfänger erkennen kann.

Die mit (*) gekennzeichneten Angaben müssen eingetragen werden!

Die Verwendung Ihrer Daten für den Newsletter können Sie jederzeit mit Wirkung für die Zukunft gegenüber der MedtriX GmbH - Geschäftsbereich rs media widersprechen ohne dass Kosten entstehen. Nutzen Sie hierfür etwaige Abmeldelinks im Newsletter oder schreiben Sie eine E-Mail an: rgb-info[at]medtrix.group.